Drugmakers forge ahead with immunotherapies

Large drugmakers and startup biotechnology companies are developing therapies that harness the body's immune system to recognize and attack tumor cells, and some drugs, such as Bristol-Myers Squibb's melanoma drug Yervoy, have shown promising results. "That these agents can produce a long-term stable response in multiple tumor types is a whole new approach to treating cancer," said Yale Cancer Center chief of medical oncology Roy Herbst. The technology could transform the way cancer is treated and refill dry drugmaker pipelines, analysts say.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide